Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 14

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 14
---
2025                                       |     | $ | 0.76 |
| Increase in pro forma net tangible book value per share attributable to new investors        |     | $ | 0.57 |
| Pro forma as adjusted net tangible book value per share after giving effect to this offering |     | $ | 1.33 |
| Pro forma dilution in net tangible book value per share to new investors                     |     | $ | 4.97 |

The information above excludes:

| ● | 7,303,307 shares of our common stock issuable upon the exercise                                                                                
 of outstanding stock options as of March 31, 2025, at a weighted average exercise price of $8.28 per share, 5,124,039 of which are exercisable 
 at a weighted average exercise price of $8.71 per share;                                                                                       |

| ● | 3,944,138 shares of our common stock issuable upon the exercise                                       
 of outstanding warrants as of March 31, 2025 at a weighted average exercise price of $7.75 per share; |

| ● | 2,521,243 additional shares of our common stock available for future issuance under our amended and restated INmune Bio Inc. 2021 stock incentive plan; and                                                     |
| ● | 654,847 shares of our common stock sold subsequent to March 31, 2025 pursuant to our “at-the-market” sales agreement with RBC Capital Markets LLC and BTIG, LLC, at a weighted average price of $7.42 per share |

<div align='center'>S-8

CAPITALIZATION</div>

The following table sets forth
our consolidated cash and cash equivalents and capitalization as of March 31, 2025. Such information is set forth on the following basis:

| ● | on an actual basis;                                                                                                                                                                                                            |
| ● | on a pro forma basis, after giving effect to (i) the issuance of 654,847 shares of common stock under the Company’s At-The-Market offering program at an average price of $7.42 per share during April, May and June 2025; and |
| ● | on a pro forma as adjusted basis, giving effect to the sale of the shares in this offering at a public offering price of $6.30 per share for investors, after deducting Placement Agent fees and estimated offering expenses.  |

You should read this table
together with the section of this prospectus supplement entitled “Use of